AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MASS

Griffith Joseph H. IV sold $125K of MASS

Griffith Joseph H. IV (Chief Financial Officer) sold 11,459 shares of 908 Devices Inc. (MASS) at $10.95 ($0.13M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Griffith Joseph H. IV
Published Aug 27, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
high confidence
Mentioned
$MASS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

The CFO's sale is modest and pre‑arranged, likely having little effect on stock price.

02

Market read

Primary insider sale filing with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Aug 27 after sale on Aug 25

Background

SEC Form 4 filing discloses insider transactions; required for transparency.

Company-level read

Ticker impact

$MASSNeutralHigh confidence
Context

CFO Griffith Joseph H. IV sold 11,459 shares for $125,476 via a 10b5-1 plan.

Expected impact

minimal short-term impact, likely negligible price movement

Evidence & confidence

Form 4 is primary source; transaction amount is small relative to market cap, typical pre‑arranged sale.

Market effects

Sector

None; the sale is company‑specific and does not affect the broader sector.

Regional

None; limited to investors monitoring insider activity.

Global

None; no global macro implications.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    908 Devices Inc.

    Issuer of the securities sold.

  • Individual
    Griffith Joseph H. IV

    Chief Financial Officer and insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MASS insider trading history →

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

finance.yahoo.com
$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

investing.com
$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

SEC EDGAR 8-K
$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

yahoo.com
$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).

yahoo.com